Virpax Pharmaceuticals, Inc.: Nasdaq/NYSE listing notice — Virpax regains Nasdaq compliance; court approves settlement with Sorrento/Scilex

Virpax Pharmaceuticals, Inc.

Nasdaq notified Virpax that closing bid price was at $1.00 or greater for 10 consecutive business days through March 14, 2024; compliance regained.
Bankruptcy Court for Southern District of Texas entered order approving settlement between Virpax, Sorrento Therapeutics, and Scilex Pharmaceuticals on March 14, 2024.
Settlement Agreement and Mutual Release incorporated by reference from prior 8-K; no financial terms disclosed in this filing.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Virpax Pharmaceuticals, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 15, 2024, Virpax Pharmaceuticals, Inc. (the “Company”), received a letter (the “Notification Letter”) from The Nasdaq Stock Market (“Nasdaq”) stating that for the last 10 consecutive business days, from March 1, through 14, 2024, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed .

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001213900-24-023188

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.